GenSci128 for solid tumors with TP53 Y220C mutation
Part of Cancer clinical trials.
This trial tests a new drug, GenSci128, for people whose solid tumors have a specific TP53 Y220C mutation. The drug aims to reactivate the p53 protein to fight cancer. It is for patients who have exhausted standard treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your tumor must have a specific change in the TP53 gene called a Y220C mutation (confirmed by a test).
- You have advanced or metastatic solid tumor that has gotten worse after standard treatment, or no standard treatment is available for you.
- You have at least one tumor that can be measured on a scan.
- You are able to take care of yourself (ECOG score 0 or 1).
- You are at least 18 years old and have a life expectancy of at least 3 months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a personalized cell therapy called TP53 R248Q TCR-T for people with advanced solid tumors that have a specific genetic change (TP53 R248Q mutation). The treatment uses your own immune cells modified to attack cancer cells, and may be an option if standard treatments are no longer working.
This trial tests a new drug called SC-102 in people with advanced solid tumors that have stopped responding to standard treatments. It aims to see if SC-102 is safe and how well it works.
This trial tests a new drug called IPG1094 for people with advanced solid tumors that have not responded to standard treatments. The goal is to see if the drug is safe and effective.
This trial tests a new drug called NTS071 in people with advanced solid tumors that have a specific mutation in the TP53 gene (called Y220C). The goal is to see if the drug is safe and can help shrink or slow the growth of the tumor.
This trial tests a new drug (called LG00313112) for people with advanced solid tumors that have a specific genetic change called TP53 Y220C. The drug aims to target this change and may help slow or stop cancer growth.
This trial tests an experimental pill called GenSci122 for people with advanced solid tumors that have stopped responding to standard treatments. The goal is to see if the drug is safe and can help shrink tumors.
Hear when a new Solid Tumors Harboring a TP53 Y220C Mutation trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.